Clinical Trial: Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and Azathioprine

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07902492) titled 'Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and Azathioprine' on Oct. 22.

Brief Summary: MAINRIPAC is a multicenter, randomized, open-label controlled clinical trial evaluating the efficacy of rituximab versus azathioprine for maintenance of remission in patients with primary angiitis of the central nervous system (PACNS). Patients are randomized 1:1 to receive either rituximab or azathioprine and are followed for 24 months, with regular clinical and brain MRI assessments to evalua...